What's on this Page
What is Reslizumab
Reslizumab (Cinqair) is a humanized monoclonal antibody that targets interleukin 5, inhibiting its action.
The drug reduces eosinophil-meditated inflammation of the airways,
It is indicated for add-on maintenance treatment of adult patients with severe asthma with an eosinophilic phenotype.
Brand Name
CINQAIR
Indications
- asthma maintenance
For asthma maintenance add-on therapy in severe asthma (eosinophilic phenotype)
Side Effects
- antibody formation
- cough
- dizziness
- dyspnea
- fatigue
- headache
- hypotension
- muscle cramps
- musculoskeletal pain
- myalgia
- nasal congestion
- new primary malignancy
- pharyngitis
- rash
- serious hypersensitivity reactions or anaphylaxis
- sinusitis
- urticaria
- vomiting
- wheezing
Monitoring Parameters
- laboratory monitoring not necessary
- pulmonary function tests (PFTs)
Contraindications
- acute bronchospasm
- breast-feeding
- children
- corticosteroid withdrawal
- deterioration of asthma
- helminth infection
- infants
- neoplastic disease
- new primary malignancy
- pregnancy
- requires a specialized care setting
- requires an experienced clinician
- serious hypersensitivity reactions or anaphylaxis
- status asthmaticus
Interactions
There are no drug interactions associated with Reslizumab products.
